CN109043055A - 一种改善亚健康状态的凉茶 - Google Patents
一种改善亚健康状态的凉茶 Download PDFInfo
- Publication number
- CN109043055A CN109043055A CN201811172238.7A CN201811172238A CN109043055A CN 109043055 A CN109043055 A CN 109043055A CN 201811172238 A CN201811172238 A CN 201811172238A CN 109043055 A CN109043055 A CN 109043055A
- Authority
- CN
- China
- Prior art keywords
- parts
- sub
- health state
- herbal tea
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000015092 herbal tea Nutrition 0.000 title claims abstract description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 48
- 230000001954 sterilising effect Effects 0.000 claims abstract description 38
- 238000012545 processing Methods 0.000 claims abstract description 36
- 240000000171 Crataegus monogyna Species 0.000 claims abstract description 34
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 33
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 33
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 33
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 33
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 33
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 33
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 33
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 33
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 33
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 33
- 239000002994 raw material Substances 0.000 claims abstract description 33
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 31
- 229920002752 Konjac Polymers 0.000 claims abstract description 29
- 150000004676 glycans Chemical class 0.000 claims abstract description 29
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 29
- 239000005017 polysaccharide Substances 0.000 claims abstract description 29
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 28
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract description 26
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 26
- 241001598107 Imperata Species 0.000 claims abstract description 26
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 25
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 25
- 244000068988 Glycine max Species 0.000 claims abstract description 25
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 25
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 24
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 24
- 235000010674 Prunella vulgaris Nutrition 0.000 claims abstract description 24
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 24
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 24
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 24
- 235000013361 beverage Nutrition 0.000 claims abstract description 23
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 22
- 235000013312 flour Nutrition 0.000 claims abstract description 22
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 238000000227 grinding Methods 0.000 claims abstract description 13
- 238000007872 degassing Methods 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 235000013373 food additive Nutrition 0.000 claims abstract description 6
- 239000002778 food additive Substances 0.000 claims abstract description 6
- 239000000047 product Substances 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims description 40
- 239000007788 liquid Substances 0.000 claims description 30
- 238000011049 filling Methods 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 21
- 238000009835 boiling Methods 0.000 claims description 20
- 235000011194 food seasoning agent Nutrition 0.000 claims description 20
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 20
- 239000008236 heating water Substances 0.000 claims description 20
- 239000011265 semifinished product Substances 0.000 claims description 20
- 239000000084 colloidal system Substances 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 17
- 239000001509 sodium citrate Substances 0.000 claims description 14
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 14
- 235000013616 tea Nutrition 0.000 claims description 12
- 230000000844 anti-bacterial effect Effects 0.000 claims description 11
- 238000007792 addition Methods 0.000 claims description 10
- 238000004090 dissolution Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000000265 homogenisation Methods 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 10
- 238000009288 screen filtration Methods 0.000 claims description 10
- 238000007789 sealing Methods 0.000 claims description 10
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 9
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 206010054949 Metaplasia Diseases 0.000 claims description 2
- 230000015689 metaplastic ossification Effects 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 235000005979 Citrus limon Nutrition 0.000 claims 1
- 244000131522 Citrus pyriformis Species 0.000 claims 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims 1
- 235000010350 erythorbic acid Nutrition 0.000 claims 1
- DINKXUCRJBUQAZ-UHFFFAOYSA-N tert-butyl 5-bromopyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CN=CC(Br)=C1 DINKXUCRJBUQAZ-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 210000004369 blood Anatomy 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 25
- 230000006872 improvement Effects 0.000 abstract description 16
- 241000411851 herbal medicine Species 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 5
- 235000019640 taste Nutrition 0.000 abstract description 4
- 208000004880 Polyuria Diseases 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 3
- 230000035619 diuresis Effects 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 44
- 230000009182 swimming Effects 0.000 description 20
- 210000003128 head Anatomy 0.000 description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 230000036541 health Effects 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 206010016256 fatigue Diseases 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 208000016255 tiredness Diseases 0.000 description 10
- 230000003867 tiredness Effects 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 206010010071 Coma Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- -1 element Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000001151 other effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000014860 sensory perception of taste Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- MKMCJLMBVKHUMS-UHFFFAOYSA-N Coixol Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000251511 Holothuroidea Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 240000007171 Imperata cylindrica Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 235000010676 Ocimum basilicum Nutrition 0.000 description 2
- 240000007926 Ocimum gratissimum Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 241000287420 Pyrus x nivalis Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000209495 Acorus Species 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 241000471262 Ardisia japonica Species 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- 229930184857 Asterin Natural products 0.000 description 1
- YWGAKIGNXGAAQR-UHFFFAOYSA-N Astin C Natural products N1C(=O)C(CO)NC(=O)C(CC)NC(=O)C2C(Cl)C(Cl)CN2C(=O)C(CC)NC(=O)CC1C1=CC=CC=C1 YWGAKIGNXGAAQR-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 241001630118 Chrysomphalus bifasciculatus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000160089 Crataegus cuneata Species 0.000 description 1
- 235000008440 Crataegus cuneata Nutrition 0.000 description 1
- 235000014283 Crataegus pinnatifida var major Nutrition 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 240000005342 Hypericum chinense Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001252483 Kalimeris Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 244000242564 Osmanthus fragrans Species 0.000 description 1
- 235000019083 Osmanthus fragrans Nutrition 0.000 description 1
- 241000588278 Osmanthus heterophyllus Species 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SNGZVXPRGLTKNU-RGMNGODLSA-N [Na].C(CC)N[C@@H](CCO)C(=O)O Chemical compound [Na].C(CC)N[C@@H](CCO)C(=O)O SNGZVXPRGLTKNU-RGMNGODLSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 108010051204 asterin Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- YTMNONATNXDQJF-UBNZBFALSA-N chrysanthemin Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-UBNZBFALSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 235000021443 coca cola Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000037111 immune power Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 150000002887 oleanolic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
Abstract
本发明公开了属于食品饮料技术领域的一种改善亚健康状态的凉茶。包括如下重量份数的原料：茅根10‑15份，大豆肽15‑20份，山楂5‑10份，魔芋粉5‑10份，葡萄籽提取物10‑15份，沙棘5‑7份，陈皮2‑6份，石菖蒲3‑5份，白茯苓1‑3份，夏枯草1‑3份，枸杞多糖1‑3份，金银花3‑5份，菊花1‑3份，食品添加剂0.01‑0.1份。本发明制备的改善亚健康状态的凉茶，选材上以中草药为主，现代工艺化产品为辅，充分利用各味草药的成分，相辅相成，充分调节凉茶的口感；制备工艺采用传统的煎煮方法，又加入现代化工艺进行水浴、研磨、均质、脱气和冷杀菌处理方式，使各原料中原生态有效成分不被破坏，补充人体所需，起到补益气血，扶正补虚，解郁祛邪，利尿行水，阻抗衰老、缓解疲劳、调解阴阳的作用。
Description
技术领域
本发明属于食品饮料技术领域，具体涉及一种改善亚健康状态的凉茶。
背景技术
近年来，由于环境污染，激烈竞争，人们的生活和工作节奏不断加快，来自社会和各方面的压力不断增加，再加上吸烟酗酒、高热量高脂肪饮食、缺乏体力劳动、生活不规律、夜生活过度等不良习惯，亚健康状态人群占我国人群的比例逐渐增多。从临床检测来看，城市里的这类群体比较集中地表现为三高一低倾向，即存在着接近临界水平的高血脂、高血糖、高血粘度和免疫功能偏低。中国亚健康学术成果研讨会数据显示：我国人15％属于健康，15％属于非健康，70％属于亚健康，亚健康人数超过9亿。亚健康已经严重地影响了人们的生活、学习和工作，成为普遍的社会问题，成为社会发展的制约因素，其危害性已被医学界认为是世纪人类健康大敌。
目前，市场上的各种饮料很多，雪碧、可口可乐等碳酸型饮料，由于含有大量糖分，对于亚健康人群是弊大于利的，红牛、乐虎、脉动等运动型饮料，主要以抗疲劳和补充矿物元素为主，起效快但持续时间短，绿茶、红茶等茶饮料，以清凉解渴为主，里面含有羟甲基甘氨酸钠这类防腐剂，不适于长期饮用，而一般凉茶也多是以驱热降火为主，起到养生保健的饮料却很少，尤其专门针对亚健康人群身体乏力、困倦懒怠、情绪低落、焦躁不安、失眠多梦、记忆力减退等症状起缓解保健作用的饮料更少，如果这种亚状态不能得到及时注意并纠正，并且长期处于亚健康状态下，很容易引起其他身心疾病，甚至影响人类的生命。
专利201410232156.2公开的一种亚健康人群养生饮料，由下述重量份的原料制成：海参10-15、雪梨70-80、苹果30-40、葡萄柚40-50、甜菊叶20-30、桂花10-20、二色补血草6-8、覆盆子10-14、罗勒子8-12、芦根1-2、合欢花2-3、罗勒1-2、紫金牛2-3、桂枝1-2、马兰1-2、丹参1-2、红景天2-3。该饮料能够有效增强体质、调节免疫、改善睡眠、滋阴补血、抗疲劳等功效，此外该饮料的制备方法简单，可适用性强，但是原料中含有较大份数的雪梨、苹果、葡萄柚，使养生饮料的糖分含量较高，对于高血糖的亚健康人群不易饮用，此外原料中含有昂贵药材海参，使得该饮料造价较高。因此，研制一款适合亚健康人群的绿色安全，及时补充人体所需，科学调理亚健康状态并起到保健作用的饮料尤为重要。
发明内容
本发明的目的在于提供一种改善亚健康状态的凉茶和制备方法。
一种改善亚健康状态的凉茶，包括如下重量份数的原料：茅根10-15份，大豆肽15-20份，山楂5-10份，魔芋粉5-10份，葡萄籽提取物10-15份，沙棘5-7份，陈皮2-6份，石菖蒲3-5份，白茯苓1-3份，夏枯草1-3份，枸杞多糖1-3份，金银花3-5份，菊花1-3份，食品添加剂0.01-0.1份。
优选地，所述改善亚健康状态的凉茶的原料还包括牛蒡3-5份。
优选地，所述改善亚健康状态的凉茶的原料还包括多鳞口蘑3-5份。
优选地，所述改善亚健康状态的凉茶食品添加剂为柠檬酸，柠檬酸钠，D-异抗坏血酸钠，羧甲基纤维素钠，木糖醇一种或一种以上。
上述改善亚健康状态的凉茶的制备方法，按照如下步骤进行：
(1)煎煮：按照重量份数，将茅根10-15份，山楂5-10份，沙棘5-7份，陈皮2-6份，石菖蒲3-5份，白茯苓1-3份，夏枯草1-3份，金银花3-5份，菊花1-3份加入等重量份数的纯净水，浸泡10分钟后过滤去除杂质，将原料放入原料罐中再加入8-10倍的纯净水，浸泡4-6小时后，用大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，再次在原料罐中加入8-10倍的纯净水，大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，合并两次的煎煮液，得煎煮液A；
(2)水浴加热，按照重量份数，将大豆肽15-20份，魔芋粉5-10份，葡萄籽提取物10-15份，枸杞多糖1-3份，加入6-8倍的水，用混合搅拌机搅拌，搅拌速度为1200-1500r/min，待充分溶解后在40-65℃的温度下进行水浴加热8-24h，得混合汁液B；
(3)研磨过滤：将所述煎煮液A和所述混合汁液B混合，用胶体研磨机研磨2-4次，胶体研磨机的转速为2000～8000r/min，用150-280目的过滤网过滤，滤渣排出，在滤液中加入食品添加剂0.01-0.1份，进行调酸处理，调酸pH为4.0-4.5，糖酸比为55-75∶1，得调配液C；
(4)均质脱气：将所述调配液C用高压均质机在均质3-5次，均质压力为20-25MPa，均质温度40-60℃，将脱气后的液体导入脱气装置，在0.05-0.10MPa压力下进行脱气处理，真空环境去除空气，得半成品凉茶D；
(5)灌装灭菌：将半成品凉茶D导入灭菌装置进行冷杀菌处理，然后采用饮料自动化生产线进行灌装、封口、检验程序处理后，即可得到改善亚健康状态的凉茶；
所述步骤(1)中还加入牛蒡3-5份。
所述步骤(1)中还加入多鳞口蘑3-5份。
所述步骤(5)中冷杀菌处理方式可以是超高压杀菌、超声波杀菌、紫外线杀菌。
本发明组方原料物优点如下：
1)茅根，又名茅草、白茅草、白茅根，为禾本科茅根属多年生草本植物，功能主治：用于吐血，尿血，热淋，水肿，黄疸，小便不利，热病烦渴，胃热呕哕，咳嗽。茅根所含的薏苡素对骨骼肌的收缩及代谢有抑制作用，还有镇静、解热镇痛等作用。茅根用于胃中烦热不适、恶心、肺热咳喘、心中烦躁、口苦、口渴、牙龈出血等，其清热利湿解毒作用较缓和。
2)大豆肽，富含22种氨基酸，其中包含9种人体不能合成的必需氨基酸。大豆肽为小分子的蛋白质，非常容易被人体吸收，适合蛋白质消化吸收不佳的人群食用，如中老年人、手术后恢复期病人、肿瘤及放化疗病人、胃肠功能不佳者等。此外，大豆肽还具有提高免疫力、增强体力、缓解疲劳、降三高等功效，还具有无豆腥味、无蛋白变性、酸性不沉淀、加热不凝固、易溶于水、流动性好等性能。
3)山楂，山里果、山里红，蔷薇科山楂属，山楂含多种有机酸，口服后增强胃液酸度，提高胃蛋白酶活性，促进蛋白质的消化；山楂味酸，刺激胃黏膜促进胃液分泌；山楂中含脂肪酶，能促进脂肪的消化；山楂含有维生素C等成分，口服可增进食欲；山楂黄酮可显著降低实验性高血脂动物的血清总胆固醇、低密度脂蛋白胆固醇和载脂蛋白B的浓度，显著升高高密度脂蛋白一胆固醇和载脂蛋白A。山楂降血脂作用是通过抑制肝脏胆固醇的合成，促进肝脏对血浆胆固醇的摄人而发挥降血脂作用。山楂黄酮还可降低动脉粥样硬化发生的危险性，起到预防动脉粥样硬化发生发展的作用。山楂对心血管系统的作用，抗心肌缺血、强心、降压和抗氧化。
4)魔芋，具有水平降血糖、降血脂、降压、散毒、养颜、通脉、减肥、通便、开胃等多功能。魔芋中含量最大的葡萄甘露聚糖具有强大的膨胀力，有超过任何一种植物胶的粘韧度，即可填充胃肠，消除饥饿感，又因所含热量微乎其微，故可控制体重，达到减肥健美的目的；魔芋中含有一种凝胶样的化学物质，具有防癌抗癌的神奇魔力，这种凝胶被人吃入体内后，能形成半透明膜衣，附着在肠壁上，阻碍各种有害物质，特别是致癌物质的吸收，所以魔芋又被称为“防癌魔衣”；魔芋还含有一种天然的抗菌素，以魔芋精粉为主要原料，配上其它原料制成食品后，魔芋能在食品表面形成抗菌膜，可防治细菌侵袭，延长贮存时间，起到保鲜防菌的作用。
5)葡萄籽提取物，是从葡萄籽中提取分离得到的一类多酚类物质,主要由原花青素、儿茶素、表儿茶素、没食子酸、表儿茶素没食子酸酯等多酚类物质组成，葡萄籽提取物是纯天然物质，是迄今发现的植物来源最高效的抗氧化剂之一，试验表明，其抗氧化效果是维生素C和维生素E的30～50倍，原花青素具有极强的活性，能抑制香烟中的致癌物，能有效清除体内多余的自由基，保护人体细胞组织免受自由基的氧化损伤，防治过敏、癌症、衰老等100多种与自由基有关的疾病，还具有加强和保护人体活性组织、稳定细胞膜以及抗酶活性等生物特性。主治功能：抗自由基、降低血脂、保护皮肤、保护大脑、抗过敏、保护血管、抗辐射、保护眼睛等功能，此外能有效地预防脑疲劳及脑部退化和引起的疾病。同时可保护血管内壁不受损伤，阻止血小板凝结成血块，减少中风的危险，有效防治心血管病、关节炎、白内障、癌症及免疫力低下。对经常上网、熬夜、长期使用电脑、手机的亚健康人群具有很好的调节和改善亚健康状态的作用。
6)沙棘，是一种落叶性灌木，沙棘果实中维生素C含量高，素有维生素C之王的美称，沙棘果实丰富的营养物质和生物活性物质，入药具有止咳化痰、健胃消食、活血散瘀之功效。现代医学研究，沙棘可降低胆固醇，缓解心绞痛发作，能治疗胃和十二指肠溃疡以及消化不良等，对慢性浅表性胃炎、萎缩性胃炎、结肠炎等病症疗效显著，还有防治冠状动脉粥样硬化性心脏病的作用。
7)陈皮，为芸香科植物橘及其栽培变种的干燥成熟果皮，用于脘腹胀满，食少吐泻，咳嗽痰多，理气健脾，燥湿化痰，对于亚健康人群中大腹便便者有很大益处，帮其消除脘腹胀满，与山楂同用，用于食积气滞，起到协同的作用。
8)石菖蒲，属天南星科、菖蒲属禾草状多年生草本植物，其根茎具气味。功能主治：化湿开胃，开窍豁痰，醒神益智。用于脘痞不饥，噤口下痢，神昏癫痫，健忘耳聋。理气，活血，散风，去湿。治癫痫，痰厥，热病神昏，健忘，气闭耳聋，心胸烦闷，胃痛，腹痛，风寒湿痹，痈疽肿毒，跌打损伤。
9)白茯苓，它功效非常广泛，不分四季，将它与各种药物配伍，不管寒、温、风、湿诸疾，都能发挥其独特功效，其功能主治：白茯苓既能健脾，又能渗湿，用于脾虚泄泻，又可为补肺脾，治气虚之辅佐药，白茯苓又能养心安神，故可用于心神不安、心悸、失眠等症。
10)夏枯草，多年生草本植物，匍匐根茎，节上生须根。夏枯草全草含有抗人免疫缺陷病毒(HIV)的酸性多粮夏枯草多糖，以齐敦果酸为苷元的三萜皂苷，含有芸香苷、金丝桃苷等苷类物质，含有熊果酸、咖啡酸及游离的齐敦果酸等有机酸，含维生素B1、维生素C、维生素K、胡萝卜素、树脂、苦味质、鞣质、挥发油、生物碱及氯化钾等无机盐。其功能主治：目赤肿痛、头痛眩晕、目珠夜痛、瘰疬、瘿瘤。
11)枸杞多糖，是一种水溶性多糖，是枸杞中最主要的活性成分，是枸杞的精华所在，易吸收。枸杞多糖具有促进免疫、抗衰老、抗肿瘤、清除自由基、抗疲劳、抗辐射、保肝、生殖功能保护和改善等作用。枸杞多糖可降低非胰岛素依赖型糖尿病血糖和血清中的MDA及一氧化氮的含量，并显著提高血清中的SOD含量，减少外围淋巴细胞的DNA损伤。枸杞多糖能降低四氧嘧啶诱导的糖尿病兔血糖和血脂的水平，降低高脂饲料喂养大鼠的血脂和血糖水平，是良好的降血糖物质。
12)金银花，又名忍冬，其功效主要是清热解毒，主治温病发热、热毒血痢、痈疽疔毒等。现代研究证明，金银花含有绿原酸、木犀草素苷等药理活性成分，对溶血性链球菌、金黄葡萄球菌等多种致病菌及上呼吸道感染致病病毒等有较强的抑制力，另外还可增强免疫力、抗早孕、护肝、抗肿瘤、消炎、解热、止血(凝血)、抑制肠道吸收胆固醇等，其临床用途非常广泛，可与其它药物配伍用于治疗呼吸道感染、菌痢、急性泌尿系统感染、高血压等40余种病症。
13)菊花，能入药治病，其中含有挥发油、菊甙、腺嘌呤、氨基酸、胆碱、水苏碱、小蘖碱、黄酮类、菊色素、维生素，微量元素等物质，可抗病原体，增强毛细血管抵抗力；其中的类黄酮物质已经被证明对自由基有很强的清除作用，而且在抗氧化，防衰老等方面卓有成效。从营养学角度分析，植物的精华在于花果。菊花花瓣中含有17种氨基酸，其中谷氨酸、天冬氨酸、脯氨酸等含量较高。此外，还富含维生素及铁、锌、铜、硒等微量元素。
14)牛蒡，含有人体必需的各种氨基酸，且含量较高，尤其是具有特殊药理作用的氨基酸含量高，天门冬氨酸占总氨基酸的25％-28％，精氨酸占总氨基酸的18％-20％，且含有Ca、Mg、Fe、Mn、Zn等人体必需的宏量元素和微量元素，牛蒡具有治疗糖尿病、高血压、高血脂、抗癌等作用。可降血糖、降血压、血脂、治疗失眠，提高人体免疫力等功效。
15)多鳞口蘑，可食用，属外生菌根菌，实体通常中等大。菌盖直径4-8cm，半球形，后期扁半球形，中部钝凸，表面干燥，褐色，密被黑褐色鳞片，中部鳞片黑色，盖边缘有絮状淡色鳞片。主要分布于西藏等地，由于其高寒环境影响，对亚健康人群状态的改善的作用不可估量，可降血糖、降血压、血脂以及提高免疫力的作用。
本发明的有益效果：本发明制备的改善亚健康状态的凉茶，在选材方面，以茅根、山楂、沙棘、陈皮、陈皮，石菖蒲，白茯苓，夏枯草，金银花和菊花等十余味中草药为原料，充分利用各味草药的成分，相辅相成，符合中医规律，又加入大豆肽、魔芋粉、葡萄籽提取物、枸杞多糖、食品添加剂这些现代工艺化产品，在充分缓解和纠正亚健康状态的基础上，进一步调节凉茶口感，增加营养物质，使亚健康状态的人群能够快速恢复健康，充满精力缓解疲劳；在制备工艺方面，中草药采用传统的煎煮方法，充分萃取出中草药的有效成分，又用了现代化工艺进行水浴、研磨、均质、脱气和冷杀菌处理方式，使各原料中的有机酸、黄酮类、花青素、多糖、氨基酸、维生素、多酚类物质和矿质微量元素等原生态有效成分不被破坏，充分保存活性，补充人体所需，清除体内自由基，用来纠正和治疗亚健康人群身体乏力、困倦懒怠、情绪低落、焦躁不安、失眠多梦、记忆力减退等症状，起到补益气血，扶正补虚，解郁祛邪，利尿行水，阻抗衰老、缓解疲劳、调解阴阳的作用。
具体实施方式
下面结合具体实施例对本发明做进一步说明。
实施例1
一种改善亚健康状态的凉茶，包括如下重量份数的原料：茅根12.5份，大豆肽17.5份，山楂7.5份，魔芋粉7.5份，葡萄籽提取物12.5份，沙棘6份，陈皮4份，石菖蒲4份，白茯苓2份，夏枯草2份，枸杞多糖2份，金银花4份，菊花2份，柠檬酸钠0.05份。
上述改善亚健康状态的凉茶的制备方法，按照如下步骤进行：
(1)煎煮：按照重量份数，将茅根12.5份，山楂7.5份，沙棘6份，陈皮4份，石菖蒲4份，白茯苓2份，夏枯草2份，金银花4份，菊花2份加入等重量份数的纯净水，浸泡10分钟后过滤去除杂质，将原料放入原料罐中再加入9倍的纯净水，浸泡5小时后，用大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，再次在原料罐中加入9倍的纯净水，大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，合并两次的煎煮液，得煎煮液A；
(2)水浴加热，按照重量份数，将大豆肽17.5份，魔芋粉7.5份，葡萄籽提取物12.5份，枸杞多糖2份，加入7倍的水，用混合搅拌机搅拌，搅拌速度为1350r/min，待充分溶解后在58℃的温度下进行水浴加热16h，得混合汁液B；
(3)研磨过滤：将所述煎煮液A和所述混合汁液B混合，用胶体研磨机研磨3次，胶体研磨机的转速为5000r/min，用210目的过滤网过滤，滤渣排出，在滤液中加入柠檬酸钠0.05份，进行调酸处理，调酸pH为4.3，糖酸比为65∶1，得调配液C；
(4)均质脱气：将所述调配液C用高压均质机在均质4次，均质压力为23MPa，均质温度50℃，将脱气后的液体导入脱气装置，在0.07MPa压力下进行脱气处理，真空环境去除空气，得半成品凉茶D；
(5)灌装灭菌：将半成品凉茶D导入灭菌装置进行超高压杀菌的冷杀菌处理，然后采用饮料自动化生产线进行灌装、封口、检验程序处理后，即可得到改善亚健康状态的凉茶。
实施例2
一种改善亚健康状态的凉茶，包括如下重量份数的原料：茅根10份，大豆肽15份，山楂5份，魔芋粉5份，葡萄籽提取物10份，沙棘5份，陈皮2份，石菖蒲3份，白茯苓1份，夏枯草1份，枸杞多糖1份，金银花3份，菊花1-3份，木糖醇0.01份。
上述改善亚健康状态的凉茶的制备方法，按照如下步骤进行：
(1)煎煮：按照重量份数，将茅根10份，山楂5份，沙棘5份，陈皮2份，石菖蒲3份，白茯苓1份，夏枯草1份，金银花3份，菊花1份加入等重量份数的纯净水，浸泡10分钟后过滤去除杂质，将原料放入原料罐中再加入8倍的纯净水，浸泡4小时后，用大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，再次在原料罐中加入8倍的纯净水，大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，合并两次的煎煮液，得煎煮液A；
(2)水浴加热，按照重量份数，将大豆肽15份，魔芋粉5份，葡萄籽提取物10份，枸杞多糖1份，加入6倍的水，用混合搅拌机搅拌，搅拌速度为1200r/min，待充分溶解后在40℃的温度下进行水浴加热8h，得混合汁液B；
(3)研磨过滤：将所述煎煮液A和所述混合汁液B混合，用胶体研磨机研磨2次，胶体研磨机的转速为2000r/min，用150目的过滤网过滤，滤渣排出，在滤液中加入木糖醇0.01份，进行调酸处理，调酸pH为4.0，糖酸比为55∶1，得调配液C；
(4)均质脱气：将所述调配液C用高压均质机在均质3次，均质压力为20MPa，均质温度40℃，将脱气后的液体导入脱气装置，在0.05MPa压力下进行脱气处理，真空环境去除空气，得半成品凉茶D；
(5)灌装灭菌：将半成品凉茶D导入灭菌装置进行超声波杀菌的冷杀菌处理，然后采用饮料自动化生产线进行灌装、封口、检验程序处理后，即可得到改善亚健康状态的凉茶。
实施例3
一种改善亚健康状态的凉茶，包括如下重量份数的原料：茅根15份，大豆肽20份，山楂10份，魔芋粉10份，葡萄籽提取物15份，沙棘7份，陈皮6份，石菖蒲5份，白茯苓3份，夏枯草3份，枸杞多糖3份，金银花5份，菊花3份，羧甲基纤维素钠0.1份。
上述改善亚健康状态的凉茶的制备方法，按照如下步骤进行：
(1)煎煮：按照重量份数，将茅根15份，山楂10份，沙棘7份，陈皮6份，石菖蒲5份，白茯苓3份，夏枯草3份，金银花5份，菊花3份加入等重量份数的纯净水，浸泡10分钟后过滤去除杂质，将原料放入原料罐中再加入10倍的纯净水，浸泡6小时后，用大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，再次在原料罐中加入10倍的纯净水，大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，合并两次的煎煮液，得煎煮液A；
(2)水浴加热，按照重量份数，将大豆肽20份，魔芋粉10份，葡萄籽提取物115份，枸杞多糖3份，加入8倍的水，用混合搅拌机搅拌，搅拌速度为1500r/min，待充分溶解后在65℃的温度下进行水浴加热24h，得混合汁液B；
(3)研磨过滤：将所述煎煮液A和所述混合汁液B混合，用胶体研磨机研磨2-4次，胶体研磨机的转速为8000r/min，用280目的过滤网过滤，滤渣排出，在滤液中加入羧甲基纤维素钠0.1份，进行调酸处理，调酸pH为4.5，糖酸比为75∶1，得调配液C；
(4)均质脱气：将所述调配液C用高压均质机在均质5次，均质压力为25MPa，均质温度60℃，将脱气后的液体导入脱气装置，在0.10MPa压力下进行脱气处理，真空环境去除空气，得半成品凉茶D；
(5)灌装灭菌：将半成品凉茶D导入灭菌装置进行超声波杀菌的冷杀菌处理，然后采用饮料自动化生产线进行灌装、封口、检验程序处理后，即可得到改善亚健康状态的凉茶。
实施例4
一种改善亚健康状态的凉茶，包括如下重量份数的原料：茅根12.5份，大豆肽17.5份，山楂7.5份，魔芋粉7.5份，葡萄籽提取物12.5份，沙棘6份，陈皮4份，石菖蒲4份，白茯苓2份，夏枯草2份，枸杞多糖2份，金银花4份，菊花2份，牛蒡4份，柠檬酸钠0.05份。
上述改善亚健康状态的凉茶的制备方法，按照如下步骤进行：
(1)煎煮：按照重量份数，将茅根12.5份，山楂7.5份，沙棘6份，陈皮4份，石菖蒲4份，白茯苓2份，夏枯草2份，金银花4份，菊花2份，牛蒡4份，加入等重量份数的纯净水，浸泡10分钟后过滤去除杂质，将原料放入原料罐中再加入9倍的纯净水，浸泡5小时后，用大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，再次在原料罐中加入9倍的纯净水，大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，合并两次的煎煮液，得煎煮液A；
(2)水浴加热，按照重量份数，将大豆肽17.5份，魔芋粉7.5份，葡萄籽提取物12.5份，枸杞多糖2份，加入7倍的水，用混合搅拌机搅拌，搅拌速度为1350r/min，待充分溶解后在58℃的温度下进行水浴加热16h，得混合汁液B；
(3)研磨过滤：将所述煎煮液A和所述混合汁液B混合，用胶体研磨机研磨3次，胶体研磨机的转速为5000r/min，用210目的过滤网过滤，滤渣排出，在滤液中加入柠檬酸钠0.05份，进行调酸处理，调酸pH为4.3，糖酸比为65∶1，得调配液C；
(4)均质脱气：将所述调配液C用高压均质机在均质4次，均质压力为23MPa，均质温度50℃，将脱气后的液体导入脱气装置，在0.07MPa压力下进行脱气处理，真空环境去除空气，得半成品凉茶D；
(5)灌装灭菌：将半成品凉茶D导入灭菌装置进行超高压杀菌的冷杀菌处理，然后采用饮料自动化生产线进行灌装、封口、检验程序处理后，即可得到改善亚健康状态的凉茶。
实施例5
一种改善亚健康状态的凉茶，包括如下重量份数的原料：茅根12.5份，大豆肽17.5份，山楂7.5份，魔芋粉7.5份，葡萄籽提取物12.5份，沙棘6份，陈皮4份，石菖蒲4份，白茯苓2份，夏枯草2份，枸杞多糖2份，金银花4份，菊花2份，多鳞口蘑4份，柠檬酸钠0.05份。
上述改善亚健康状态的凉茶的制备方法，按照如下步骤进行：
(1)煎煮：按照重量份数，将茅根12.5份，山楂7.5份，沙棘6份，陈皮4份，石菖蒲4份，白茯苓2份，夏枯草2份，金银花4份，菊花2份，多鳞口蘑4份，加入等重量份数的纯净水，浸泡10分钟后过滤去除杂质，将原料放入原料罐中再加入9倍的纯净水，浸泡5小时后，用大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，再次在原料罐中加入9倍的纯净水，大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，合并两次的煎煮液，得煎煮液A；
(2)水浴加热，按照重量份数，将大豆肽17.5份，魔芋粉7.5份，葡萄籽提取物12.5份，枸杞多糖2份，加入7倍的水，用混合搅拌机搅拌，搅拌速度为1350r/min，待充分溶解后在58℃的温度下进行水浴加热16h，得混合汁液B；
(3)研磨过滤：将所述煎煮液A和所述混合汁液B混合，用胶体研磨机研磨3次，胶体研磨机的转速为5000r/min，用210目的过滤网过滤，滤渣排出，在滤液中加入柠檬酸钠0.05份，进行调酸处理，调酸pH为4.3，糖酸比为65∶1，得调配液C；
(4)均质脱气：将所述调配液C用高压均质机在均质4次，均质压力为23MPa，均质温度50℃，将脱气后的液体导入脱气装置，在0.07MPa压力下进行脱气处理，真空环境去除空气，得半成品凉茶D；
(5)灌装灭菌：将半成品凉茶D导入灭菌装置进行超高压杀菌的冷杀菌处理，然后采用饮料自动化生产线进行灌装、封口、检验程序处理后，即可得到改善亚健康状态的凉茶。
实施例6
一种改善亚健康状态的凉茶，包括如下重量份数的原料：茅根12.5份，大豆肽17.5份，山楂7.5份，魔芋粉7.5份，葡萄籽提取物12.5份，沙棘6份，陈皮4份，石菖蒲4份，白茯苓2份，夏枯草2份，枸杞多糖2份，金银花4份，菊花2份，山牛蒡4份，柠檬酸钠0.05份。
上述改善亚健康状态的凉茶的制备方法，按照如下步骤进行：
(1)煎煮：按照重量份数，将茅根12.5份，山楂7.5份，沙棘6份，陈皮4份，石菖蒲4份，白茯苓2份，夏枯草2份，金银花4份，菊花2份，山牛蒡4份，加入等重量份数的纯净水，浸泡10分钟后过滤去除杂质，将原料放入原料罐中再加入9倍的纯净水，浸泡5小时后，用大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，再次在原料罐中加入9倍的纯净水，大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，合并两次的煎煮液，得煎煮液A；
(2)水浴加热，按照重量份数，将大豆肽17.5份，魔芋粉7.5份，葡萄籽提取物12.5份，枸杞多糖2份，加入7倍的水，用混合搅拌机搅拌，搅拌速度为1350r/min，待充分溶解后在58℃的温度下进行水浴加热16h，得混合汁液B；
(3)研磨过滤：将所述煎煮液A和所述混合汁液B混合，用胶体研磨机研磨3次，胶体研磨机的转速为5000r/min，用210目的过滤网过滤，滤渣排出，在滤液中加入柠檬酸钠0.05份，进行调酸处理，调酸pH为4.3，糖酸比为65∶1，得调配液C；
(4)均质脱气：将所述调配液C用高压均质机在均质4次，均质压力为23MPa，均质温度50℃，将脱气后的液体导入脱气装置，在0.07MPa压力下进行脱气处理，真空环境去除空气，得半成品凉茶D；
(5)灌装灭菌：将半成品凉茶D导入灭菌装置进行超高压杀菌的冷杀菌处理，然后采用饮料自动化生产线进行灌装、封口、检验程序处理后，即可得到改善亚健康状态的凉茶。
实施例7
一种改善亚健康状态的凉茶，包括如下重量份数的原料：茅根12.5份，大豆肽17.5份，山楂7.5份，魔芋粉7.5份，葡萄籽提取物12.5份，沙棘6份，陈皮4份，石菖蒲4份，白茯苓2份，夏枯草2份，枸杞多糖2份，金银花4份，菊花2份，白蘑菇4份，柠檬酸钠0.05份。
上述改善亚健康状态的凉茶的制备方法，按照如下步骤进行：
(1)煎煮：按照重量份数，将茅根12.5份，山楂7.5份，沙棘6份，陈皮4份，石菖蒲4份，白茯苓2份，夏枯草2份，金银花4份，菊花2份，白蘑菇4份，加入等重量份数的纯净水，浸泡10分钟后过滤去除杂质，将原料放入原料罐中再加入9倍的纯净水，浸泡5小时后，用大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，再次在原料罐中加入9倍的纯净水，大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，合并两次的煎煮液，得煎煮液A；
(2)水浴加热，按照重量份数，将大豆肽17.5份，魔芋粉7.5份，葡萄籽提取物12.5份，枸杞多糖2份，加入7倍的水，用混合搅拌机搅拌，搅拌速度为1350r/min，待充分溶解后在58℃的温度下进行水浴加热16h，得混合汁液B；
(3)研磨过滤：将所述煎煮液A和所述混合汁液B混合，用胶体研磨机研磨3次，胶体研磨机的转速为5000r/min，用210目的过滤网过滤，滤渣排出，在滤液中加入柠檬酸钠0.05份，进行调酸处理，调酸pH为4.3，糖酸比为65∶1，得调配液C；
(4)均质脱气：将所述调配液C用高压均质机在均质4次，均质压力为23MPa，均质温度50℃，将脱气后的液体导入脱气装置，在0.07MPa压力下进行脱气处理，真空环境去除空气，得半成品凉茶D；
(5)灌装灭菌：将半成品凉茶D导入灭菌装置进行超高压杀菌的冷杀菌处理，然后采用饮料自动化生产线进行灌装、封口、检验程序处理后，即可得到改善亚健康状态的凉茶。
实施例8
一种改善亚健康状态的凉茶，包括如下重量份数的原料：茅根12.5份，大豆肽17.5份，山楂7.5份，魔芋粉7.5份，葡萄籽提取物12.5份，沙棘6份，陈皮4份，石菖蒲4份，白茯苓2份，夏枯草2份，枸杞多糖2份，金银花4份，菊花2份，青皮草4份，柠檬酸钠0.05份。
上述改善亚健康状态的凉茶的制备方法，按照如下步骤进行：
(1)煎煮：按照重量份数，将茅根12.5份，山楂7.5份，沙棘6份，陈皮4份，石菖蒲4份，白茯苓2份，夏枯草2份，金银花4份，菊花2份，青皮草4份，加入等重量份数的纯净水，浸泡10分钟后过滤去除杂质，将原料放入原料罐中再加入9倍的纯净水，浸泡5小时后，用大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，再次在原料罐中加入9倍的纯净水，大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，合并两次的煎煮液，得煎煮液A；
(2)水浴加热，按照重量份数，将大豆肽17.5份，魔芋粉7.5份，葡萄籽提取物12.5份，枸杞多糖2份，加入7倍的水，用混合搅拌机搅拌，搅拌速度为1350r/min，待充分溶解后在58℃的温度下进行水浴加热16h，得混合汁液B；
(3)研磨过滤：将所述煎煮液A和所述混合汁液B混合，用胶体研磨机研磨3次，胶体研磨机的转速为5000r/min，用210目的过滤网过滤，滤渣排出，在滤液中加入柠檬酸钠0.05份，进行调酸处理，调酸pH为4.3，糖酸比为65∶1，得调配液C；
(4)均质脱气：将所述调配液C用高压均质机在均质4次，均质压力为23MPa，均质温度50℃，将脱气后的液体导入脱气装置，在0.07MPa压力下进行脱气处理，真空环境去除空气，得半成品凉茶D；
(5)灌装灭菌：将半成品凉茶D导入灭菌装置进行超高压杀菌的冷杀菌处理，然后采用饮料自动化生产线进行灌装、封口、检验程序处理后，即可得到改善亚健康状态的凉茶。
实验例1：
按照实施例1-8的制备方法，各取30瓶灌装规格为500ml的样品，分别进行小鼠动物疲劳实验。选择4周龄SPF级雄性昆明小鼠90只，体质量18-22g，实验前全部小鼠适应性喂养7d，室温22-26℃，相对湿度40％-60％，每日明暗交替12h，所有小鼠分笼饲养，5只/笼，自由饮水、采食，适应一周后，100只小鼠随机分成10组(每组10只)，将第1组设为正常对照组，第2组设为疲劳模型组，第3-10分别设为实施例组。
给凉茶前实验：实验前1d禁食，称量各小组的小鼠质量，并对小鼠进行负5％体质量力竭游泳，至小鼠鼻尖沉入水面10s为止，为小鼠的力竭游泳时间，记录游泳时间。
给凉茶后实验：1-2组灌喂蒸馏水，3-10组中每一组灌喂一种实施例的上述产品，每天的灌喂量为40ml/kg，每日早晚各1次，连续灌喂30天，除正常对照组不做任何处理外，其余各组采用强迫小鼠每天水中站立8h，连续30d，制备疲劳亚健康小鼠模型。30d后称量各小组的小鼠质量，并对小鼠进行负5％体质量力竭游泳，至小鼠鼻尖沉入水面10s为止，为小鼠的力竭游泳时间，记录游泳时间。
首次力竭游泳时间为开始实验第1d小鼠的力竭游泳时间，即给凉茶和造模前的力竭游泳时间，此时小鼠为正常状态。末次力竭游泳时间为实验第30d小鼠的力竭游泳时间。每组进行游泳时间统计分析，结果见表1。
表1实验各小组小鼠力竭游泳时间比较(n＝10)
| 组别 | 首次力竭游泳时间(min) | 末次力竭游泳时间(min) |
| 正常对照组 | 23.6±0.5 | 22.3±0.5* |
| 疲劳模型组 | 22.9±0.3 | 12.3±0.5* |
| 实施例1组 | 23.1±0.5 | 17.3±0.3 |
| 实施例2组 | 23.7±0.2 | 17.9±0.5 |
| 实施例3组 | 23.8±0.5 | 17.6±0.4 |
| 实施例4组 | 24.1±0.7 | 20.6±0.5* |
| 实施例5组 | 23.8±0.5 | 19.9±0.3* |
| 实施例6组 | 23.5±0.6 | 18.0±0.5 |
| 实施例7组 | 23.8±0.4 | 17.5±03 |
| 实施例8组 | 23.7±0.3 | 20.9±0.6* |
注：*代表与实施例1组比较P<0.05
由表1可以得出，在首次竭游泳时间方面：各个小组的小鼠上无显著差异，说明各小组的小鼠无疲劳状态；在末次力竭游泳时间方面，实施例1-3组、实施例6-7组相当，没有显著差，正常对照组显著高于实施例1组，说明小鼠在没有疲劳的情况下比，末次游泳时间长于经历过疲劳的实施例1组，疲劳模型组显著低于实施例1组，说明小鼠经历同等疲劳程度后，实施例1组的凉茶对于小鼠有明显改善和缓解疲劳的效果，实施例4-5组、实施例8组显著高于实施例1组，说明小鼠经历同等疲劳程度后，实施例4-5组、实施例8组的凉茶相比实施例1组的凉茶，改善和缓解疲劳的效果更佳。
实验例2：
按照实施例1-8的制备方法，各取30瓶灌装规格为500ml的样品，分别进行小鼠动物疲劳实验。选择4周龄SPF级雄性昆明小鼠90只，体质量18-22g，实验前全部小鼠适应性喂养7d，室温22-26℃，相对湿度40％-60％，每日明暗交替12h，所有小鼠分笼饲养，5只/笼，自由饮水、采食，适应一周后，100只小鼠随机分成10组(每组10只)，将第1组设为正常对照组，第2组设为疲劳模型组，第3-10分别设为实施例组。1-2组灌喂生理盐水，3-10组中每一组灌喂一种实施例的上述产品，每天的灌喂量为40ml/kg，每日早晚各1次，连续灌喂30天，除正常对照组不做任何处理外，其余各组采用强迫小鼠每天水中站立8h，连续30d，制备疲劳亚健康小鼠模型。
(1)于最后一次灌喂生理盐水或者凉茶后1.5h，将各组小鼠置于游泳箱中不负重游泳30min，游泳结束后立即采血，加入抗凝素，室温静置3h，离心20min，立即检查血浆中的尿素氮和乳酸，结果见表2。
表2实验各小组小鼠乳酸和尿素氮的含量(n＝10)
注：*代表与实施例1组比较P<0.05
由表2可以得出，实施例1-3组、实施例6-7组的乳酸相当，没有显著差异，正常对照组、疲劳模型组的乳酸显著高于实施例1组，说明正常对照组小鼠和疲劳模型组小鼠在运动完后体内乳酸高于实施例1组，实施例1组的凉茶对降低小鼠体内乳酸有较好的效果，实施例4-5组、实施例8组的乳酸显著低于实施例1组，说明实施例4-5、实施例8制备的凉茶对降低小鼠体内乳酸的效果比实施例1组更佳。实施例1-3组、实施例6-7组的尿素氮相当，没有显著差异，正常对照组、疲劳模型组的乳酸显著高于实施例1组，实施例4-5组、实施例8组的尿素氮显著低于实施例1组。
(2)将各小组的小鼠脱臼处死，取小鼠的比目鱼肌，测定小鼠骨骼肌丙二醛(MDA)、超氧化物歧化酶(SOD)和总抗氧化能力(TAC)，结果见表3。
表3实验各小组小鼠骨骼肌MDA/SOD/TAC水平(n＝10)
注：*代表与实施例1组比较P<0.05
由表3可以得出，实施例1-3组、实施例6-7组的丙二醇相当，无显著性差异，正常对照组、实施例4-5组、实施例8组的丙二醇显著低于实施例1组，实施例4-5组、实施例8组的丙二醇与正常对照组含量相当，但稍微高于正常对照组，疲劳模型组的丙二醇显著高于实施例1组。实施例1-3组、实施例6-7组的超氧化物歧化酶相当，无显著性差异，正常对照组、实施例4-5组、实施例8组的超氧化物歧化酶显著高于实施例1组，实施例4-5组、实施例8组的超氧化物歧化酶与正常对照组含量相当，但稍微低于正常对照组，疲劳模型组的丙二醇显著低于实施例1组。实施例1-3组、实施例6-7组的总抗氧化能力相当，无显著性差异，正常对照组、实施例4-5组、实施例8组的总抗氧化能力显著高于实施例1组，实施例4-5组、实施例8组的总抗氧化能力与正常对照组相当，但稍微低于正常对照组，疲劳模型组的总抗氧化能力显著低于实施例1组。通过测定小鼠骨骼肌丙二醛、超氧化物歧化酶和总抗氧化能力，提示本实施例的凉茶能够提高亚健康小鼠的抗氧化能力而减少氧化应激损伤。
(3)凉茶的毒性试验：将脱臼处死的小鼠进行病理组织检查，肉眼所见各组小鼠与正常对照组相比，小鼠的心、肝、脾、肺、肾、胃、肠均正常，显微镜下观察各小组与正常对照组相比，小鼠的心、肝、脾、肺、肾，胃、肠均未见异常病变。对预先采集的小鼠血液进行生化检查，结果见表4。
表4实验各小组小鼠血液生化检查(n＝10)
由表4可以得出，各组小鼠的血液生化检查的总胆固醇、肌酐、谷丙转氨酶含量相当，无显著性差异，说明该凉茶无毒副作用。
实验例3：
按照实施例1-8的制备方法，各取20瓶灌装规格为300ml的样品进行感官评定，受试人数为160人，随机分给23-59岁的办公室白领人群进行品尝，品尝每瓶饮料并进行感官评分，感官评定标准如下：
(1)色泽：鲜亮透明微红色，分值8-10；鲜亮度透明呈深红色，分值4-7；色泽暗淡，分值0-3。
(2)气味：有中草药独特香气，气味清香，分值8-10；有中草药香气较淡，夹杂其它气味，分值4-7；无香气，分值0-3。
(3)滋味：味感协调均和，酸甜可口，分值8-10；味感一般，酸甜一般，分值4-7；味感较差，酸涩或无味道，分值0-3。
(4)组织状态：组织细腻，均匀无杂质，分值8-10；稍许沉淀或浑浊，分值4-7；沉淀较多，浑浊严重，分值0-3。
白领人群感官评定完成后进行统计分析，结果见表5。
表5白领人群感官评定凉茶结果(n＝20)
注：*代表与实施例1组比较P<0.05
由表5可以得出，实施例1-3，实施例6-7的色泽相当，没有显著差异，实施例4-5、实施例8的色泽显著高于实施例1。实施例1-3，实施例5-7的风味相当，没有显著差异，实施例4、实施例8的风味显著高于实施例1。实施例1-4，实施例6-7的滋味相当，没有显著差异，实施例5、实施例8的滋味显著高于实施例1。实施例1-3，实施例6-7的组织状态相当，没有显著差异，实施例4-5、实施例8的组织状态显著高于实施例1。
实验例4：
临床试验：筛选亚健康状态人群450例，随机分为9组，每组50人，各组饮用凉茶前在性别、年龄、病因构成等方面的差异均无显著性(P>0.05)，表明组间均衡性较好，具有可比性。
筛选亚健康状态人群符合以下9项临界指标之一，即诊断为亚健康：(1)体重指数(BMI)≥25kg/m2或男性腰围≥102cm、女性腰围≥88c m；(2)收缩压为15.96-18.49kP a(120～139mmHg)，舒张压为10.64-11.84kPa(80～89mmHg)；(3)甘油三酯(TG)≥1.69mmol/L；(4)总胆固醇(TC)≥5.17mmol/L；(5)血糖为6.1-7.0mmol/L(110～125mg/dL)；(6)估算肾小球滤过率(eGFR)为60-90mL/(min·1.73m 2)且无蛋白尿；(7)脂肪肝1期但无肝功能异常，或肝功能异常但无脂肪肝；(8)血浆硫代巴比妥酸反应产物(TBARS)≥5.09pmol/L；(9)睡眠质量不佳且问卷不适症状≥1项。
将9组中的1组设为对照组，其余8组设为实施例组，实施例组的每1组饮用按照实施例1-8的制备方法制备的凉茶，每天早晚各1次，每次100ml，对照组饮用等量的市场上流行的杜仲茶，每组均以1个月为期限，到期后进行疗效性观察，并统计饮用凉茶前后的症状改善情况。
疗效性观察指标为：身体乏力、困倦懒怠、情绪低落、焦躁不安、失眠多梦、记忆力减退、食欲不振、多汗、腰膝酸软、头晕目眩、咽燥舌红、手足心热等。疗效评定标准如下：(1)痊愈：主要症状消失，症状改善率在90％以上；②显效：主要症状显著减轻，症状改善率在60％-90％之间：③有效：主要症状和次要症状及体征有所改善，症状改善率在40％-60％之间；④无效：用药前后症状无明显改善，症状改善率不足40％，各项指数均无改善。疗效统计情况见表6。
表6各小组亚健康状态人群饮用凉茶后症状改善情况(n＝50)
| 实验组 | 痊愈 | 显效 | 有效 | 无效 | 总有效率(％) |
| 对照组 | 4 | 10 | 15 | 21 | 58.0* |
| 实施例1组 | 12 | 20 | 10 | 8 | 84.0 |
| 实施例2组 | 11 | 22 | 10 | 7 | 86.0 |
| 实施例3组 | 11 | 23 | 9 | 7 | 86.0 |
| 实施例4组 | 15 | 21 | 9 | 5 | 90.0* |
| 实施例5组 | 14 | 22 | 10 | 4 | 92.0* |
| 实施例6组 | 12 | 24 | 8 | 6 | 88.0 |
| 实施例7组 | 12 | 20 | 11 | 7 | 85.0 |
| 实施例8组 | 16 | 24 | 7 | 3 | 94.0* |
注：*代表与实施例1组比较P<0.05
由表6可以得出，实施例1-3组、实施例6-7组的总有效率相当，无显著差异，在90％以下；对照组的总有效率显著低于实施例1组，实施例4-5组、实施例8组的总有效率显著高于实施例1组，在90％以上，说明由本发明制备的凉茶具有改善亚健康状态的作用。
Claims (8)
1.一种改善亚健康状态的凉茶，其特征在于，包括如下重量份数的原料：茅根10-15份，大豆肽15-20份，山楂5-10份，魔芋粉5-10份，葡萄籽提取物10-15份，沙棘5-7份，陈皮2-6份，石菖蒲3-5份，白茯苓1-3份，夏枯草1-3份，枸杞多糖1-3份，金银花3-5份，菊花1-3份，食品添加剂0.01-0.1份。
2.根据权利要求1所述改善亚健康状态的凉茶，其特征在于，所述改善亚健康状态的凉茶的原料还包括牛蒡3-5份。
3.根据权利要求1所述改善亚健康状态的凉茶，其特征在于，所述改善亚健康状态的凉茶的原料还包括多鳞口蘑3-5份。
4.根据权利要求1所述改善亚健康状态的凉茶，其特征在于，所述食品添加剂为柠檬酸，柠檬酸钠，D-异抗坏血酸钠，羧甲基纤维素钠，木糖醇一种或者一种以上。
5.权利要求1所述改善亚健康状态的凉茶的制备方法，其特征在于，按照如下步骤进行：
（1）煎煮：按照重量份数，将茅根10-15份，山楂5-10份，沙棘5-7份，陈皮2-6份，石菖蒲3-5份，白茯苓1-3份，夏枯草1-3份，金银花3-5份，菊花1-3份加入等重量份数的纯净水，浸泡10分钟后过滤去除杂质，将原料放入原料罐中再加入8-10倍的纯净水，浸泡4-6小时后，用大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，再次在原料罐中加入8-10倍的纯净水，大火煎煮至沸腾，改小火煎煮3小时，抽出煎煮液，合并两次的煎煮液，得煎煮液A；
（2）水浴加热，按照重量份数，将大豆肽15-20份，魔芋粉5-10份，葡萄籽提取物10-15份，枸杞多糖1-3份，加入6-8倍的水，用混合搅拌机搅拌，搅拌速度为 1200 -1500r /min，待充分溶解后在40-65℃的温度下进行水浴加热8-24h，得混合汁液B；
（3）研磨过滤：将所述煎煮液A和所述混合汁液B混合，用胶体研磨机研磨2-4次，胶体研磨机的转速为2000~8000 r/min，用150-280目的过滤网过滤，滤渣排出，在滤液中加入食品添加剂0.01-0.1份，进行调酸处理，调酸pH 为4.0-4.5，糖酸比为55-75∶1，得调配液C；
（4）均质脱气：将所述调配液C用高压均质机在均质3-5次，均质压力为20-25MPa，均质温度40-60℃，将脱气后的液体导入脱气装置，在0.05-0.10MPa压力下进行脱气处理，真空环境去除空气，得半成品凉茶D；
（5）灌装灭菌：将半成品凉茶D导入灭菌装置进行冷杀菌处理，然后采用饮料自动化生产线进行灌装、封口、检验程序处理后，即可得到改善亚健康状态的凉茶。
6.根据权利要求5所述改善亚健康状态的凉茶的制备方法，其特征在于，所述步骤（1）中还加入牛蒡3-5份。
7.根据权利要求5所述改善亚健康状态的凉茶的制备方法，其特征在于，所述步骤（1）中还加入多鳞口蘑3-5份。
8.根据权利要求5所述改善亚健康状态的凉茶的制备方法，其特征在于，所述步骤（5）中冷杀菌处理方式可以是超高压杀菌、超声波杀菌、紫外线杀菌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811172238.7A CN109043055A (zh) | 2018-10-09 | 2018-10-09 | 一种改善亚健康状态的凉茶 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811172238.7A CN109043055A (zh) | 2018-10-09 | 2018-10-09 | 一种改善亚健康状态的凉茶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109043055A true CN109043055A (zh) | 2018-12-21 |
Family
ID=64763705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811172238.7A Withdrawn CN109043055A (zh) | 2018-10-09 | 2018-10-09 | 一种改善亚健康状态的凉茶 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109043055A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112544758A (zh) * | 2021-01-15 | 2021-03-26 | 张崇清 | 一种提高人体机能、预防疾病的健康饮用品及其制备方法 |
| CN112970905A (zh) * | 2021-03-27 | 2021-06-18 | 贵州医科大学 | 一种复合凉茶饮料及其制备方法 |
-
2018
- 2018-10-09 CN CN201811172238.7A patent/CN109043055A/zh not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112544758A (zh) * | 2021-01-15 | 2021-03-26 | 张崇清 | 一种提高人体机能、预防疾病的健康饮用品及其制备方法 |
| CN112970905A (zh) * | 2021-03-27 | 2021-06-18 | 贵州医科大学 | 一种复合凉茶饮料及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107296949A (zh) | 药食同源复合制剂及其制备方法和应用 | |
| CN102988638B (zh) | 一种青钱柳叶降脂降糖保健茶及其制备方法 | |
| CN107184856A (zh) | 一种具有润燥通便清肝明目功效的沙棘复合茶及其制备工艺 | |
| CN103549052B (zh) | 一种美颜减肥茶及其制备方法 | |
| CN102048224B (zh) | 一种祛黄褐斑美容养颜红枣保健饮料及其生产工艺 | |
| CN102258708A (zh) | 一种养生酒及其制备方法 | |
| CN103859378A (zh) | 一种有助于降低血糖的养生保健食品配方及其制备方法 | |
| CN106562428A (zh) | 一种美颜美体膏滋及其制备方法 | |
| CN105124605A (zh) | 一种保健咀嚼片及其制备方法 | |
| CN104673578A (zh) | 具有保健功效的sod葡萄酒及制备方法 | |
| CN106359720A (zh) | 一种清咽利喉和润肺清火的保健茶及其制备方法 | |
| CN107333926A (zh) | 一种沙棘保健茶及其制备工艺 | |
| CN104068177A (zh) | 天然植物保健益寿茶 | |
| CN110151983A (zh) | 一种用于补肾益气的中药制剂及其制备方法 | |
| CN109043055A (zh) | 一种改善亚健康状态的凉茶 | |
| KR20100067575A (ko) | 해조류 매생이를 함유하는 공진환의 제조 | |
| KR20130009901A (ko) | 혈행개선 및 기력보강과 골다공증 예방을 위한 건강식품 조성물 | |
| CN107998240A (zh) | 一种提神醒脑缓解疲劳清咽保健含片的配方及其制备方法 | |
| KR20100077781A (ko) | 발기부전에 효과적인 기능성 분말의 제조 방법, 이에 의한 기능성 분말을 포함하는 기능성 보조식품 | |
| CN105994840A (zh) | 一种铁皮石斛降压保健茶及其制作方法 | |
| CN103750096A (zh) | 富含植物精华的蜂胶蜜及其制备方法 | |
| CN105146392A (zh) | 一种营养奶昔粉及其制备方法 | |
| CN105394279A (zh) | 一种添加中药的降脂减肥茶及其制备方法 | |
| KR20210041387A (ko) | 갈화 추출물 및 차전자피 분말을 함유한 숙취해소용 천연차 및 그 제조방법 | |
| CN104323388A (zh) | 一种饮料原液、菊花苗复合植物饮料及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181221 |
|
| WW01 | Invention patent application withdrawn after publication |